NuclearMedicineFisson/ReactorProductsCyclotronProductsDefinitionofRadiopharmaceuticalIdealRadiopharmaceuticalforImaging-FactorstoConsiderIdealPhysicalCharacteristicsofImagingRadiopharmaceuticalRadioactiveDecayProcessesDiagnosticNuclearMedicineAnatomicvs.PhysiologicImagingHowdoesPhysiologicImagingWork?Anatomyvs.PhysiologyGammaCameraGammaCameraConsistsof…SodiumIodideDetectorSodiumIodideDetector,cont’d...CollimatorGammaCameraBasics*GEWholeBodyGammaCameraSPECTImagingMo-99/Tc-99mGeneratorColumnChromatographyCardiacInfarction201TlClRest99mTc-SestamibiStressTestCardiacIschemia201TlClRest99mTc-SestamibiStressTest(MDP)NormalCanineBoneScanRibMetastasis11-yearoldboywithaonemonthhistoryofrightkneepainIncreaseactivityintherighttibiaDiagnosis:OsteosarcomaMetastaticProstateCarcinomaImaging99mTc-HDPPrincipleofPETImaging[18F]Fluorodeoxyglucose(FDG)PETTherapeuticNuclearMedicineFissionproductsusefulinnuclearmedicineinclude:99Mo,131I,133Xe,137Csand90SrDifferentiatedThyroidCarcinoma5mCiNa131IImagingTreatmentPlanning48hp.i.DifferentiatedThyroidCarcinomaTherapy105mCiNa131I27hp.i.DifferentiatedThyroidCarcinomaPostSurgicalResectionTherapy57CoFloodSource+105mCiNa131IDifferentiatedThyroidCarcinoma201TlCland99mTc-SestamibiImaging4monthsafterNa131ITherapyCanineOsteosarcomaStoryofQuadraMetTM--IOneofOurFirstPatientsBoneScansofCaninePatientResultsofClinicalTrialof153Sm-EDTMPinCanineOsteosarcomaStoryofQuadraMet™--II153Sm-EDTMP[QuadraMet]ExperimentalNuclearMedicineTargetingvector(e.g.,mAb,peptidehormone,smallmolecule,etc.)Radionuclide(e.g.,diagnostic–99mTc,111In,etc.;therapeutic–188Re,90Y,177Lu,etc.)Bifunctionalchelatingagent(BCA)LinkerorspacerHypothesis1ReceptorTargetingforMolecularImagingandTherapyInternalizingvs.Non-internalizingReceptorsPeptideNucleicAcidCellularDeliveryofPNADOTA-Tyr3-OctreotatePNAandPeptideConjugatesMicroSPECT/CTUsing111In-labeledPNAandPeptideConjugates(1h,48h)Bcl-2mRNAExpressionLevelsinMec-1andRamosCellsMicroSPECT/CTUsing111In-DOT